lifestyle.pspl.com

Author: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Announces First Quarter 2026 Financial Results

May 14, 2026
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

May 7, 2026
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M

May 5, 2026
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy

May 4, 2026
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

April 30, 2026
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026

February 10, 2026